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Abstract
Background: Endogenous sex hormone levels have been
associated with increased breast cancer risk in post-
menopausal women in several prospective studies.
However, it remains unclear to what extent serum
hormone-breast cancer associations differ with receptor
status.
Methods: Associations between serum sex hormone
levels and breast cancer risk were assessed in a nested
case-control study on postmenopausal women of the
ORDET cohort. After a median follow-up of 13.5 years,
165 women developed breast cancer. Relative risks of
developing breast cancer were estimated by conditional
logistic regression.
Results: Total and free testosterone levels were directly
associated with breast cancer risk [relative risk, 3.28
(95% confidence interval, 1.93-5.55) and 2.86 (95%
confidence interval, 1.66-4.94), respectively, for highest
versus lowest quartile]. When relations between hor-
mone level and risk of breast cancer expressing various
receptor combinations were assessed, high total testos-
terone was significantly associated with increased risk
of estrogen receptor–positive cancers, irrespective of
progesterone receptor status. High total testosterone
was also associated with increased risk of both human
epidermal growth factor receptor 2 (HER2)–negative
(HER2) and HER2+ cancers. High estradiol tended to
be associated with increased risk of HER2 cancer and
inversely associated with HER2+ cancer, with signi-
ficant (P = 0.027) heterogeneity between HER2+ and
HER2 cancers. However, there were relatively few
HER2+ cases.
Conclusions: This study provides further evidence
that high levels of circulating testosterone increase
the risk of developing breast cancer in postmeno-
pausal women. The cancers that develop are mainly
estrogen receptor positive. Although HER2+ and
HER2 breast cancers were both associated with high
total testosterone, they showed opposing associations
with estrogen. (Cancer Epidemiol Biomarkers Prev
2009;18(1):169–76)
Introduction
Hormone-related factors such as early menarche, late
menopause, and use of postmenopausal hormone ther-
apy have been known for some time to be associated
with increased risk of breast cancer (1). The extensive
review of Bernstein and Ross (2) found substantial
evidence that endogenous sex hormones play a role in
the development of breast cancer. Subsequently, high
serum levels of estrogens and androgens in postmeno-
pausal women were related to increased breast cancer
risk in several prospective studies (3-6), and a pooled
analysis of nine prospective studies found a strong
association of breast cancer risk with serum concen-
trations of endogenous sex hormones in postmenopausal
women (7). The Nurses Health Study (8) and the large
European Prospective Study into Cancer and Nutrition
(9) reached similar conclusions.
However, it remains unclear to what extent serum
hormone-breast cancer associations differ with breast
cancer subtype, such as those defined by estrogen
receptor (ER) or progesterone receptor (PR) status, in
part because few studies have investigated this area (8,
10, 11). It is known that tumors overexpressing human
epidermal growth factor receptor 2 (HER2) constitute a
distinct subtype (comprising 20-25%) of breast cancers
(12, 13); however, we are aware of only one study that
addressed the role of hormonal risk factors in HER2+
cancers (14).
To further investigate the influence of sex hormone
levels in promoting specific breast cancer subtypes, we
expanded our previous nested case-control study on the
ORDET cohort (6), extending follow-up to the end of
2003, by which time 165 postmenopausal breast cases
had been diagnosed. We assessed associations between
endogenous hormone levels and breast cancer risk and
also investigated whether associations varied with the
hormone receptor and HER2 status of the cancers
diagnosed.
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Materials and Methods
Between June 1987 and June 1992, 10,786 healthy women,
aged 35 to 69 y, residents of Varese province, Northern
Italy, participated in the prospective ORDET study. All
members of the cohort were volunteers recruited from
the general population through public meetings; radio,
television, and newspaper advertising; and from among
those attending early diagnosis units for breast cancer.
Women were excluded if they had undergone hormone
treatment in the 3 mo before admission, had chronic or
acute liver disease, or had received bilateral ovariectomy.
These women completed dietary and lifestyle ques-
tionnaires, had their anthropometric measurements
recorded by trained nurses, and gave blood and urine
samples. This study was approved by the Ethical Review
Board of the National Cancer Institute of Milan.
Cancer incidence information, available from the local
cancer registry (Varese Cancer Registry), was linked to
the ORDET database to identify breast cancer cases
incident up to end of December 2003. Less than 0.3% of
breast cancer cases are known to Varese Cancer Registry
by death certificate only, and 87.3% of all but female skin
cancer cases are confirmed microscopically through
pathology reports (95.0% for breast cancer cases; ref.
15). The completeness of reporting to the cancer registry
is 98.7% for all but skin cancer sites and 99.2% for breast
cancer (16).
After excluding women diagnosed with cancer before
enrollment (except nonmelanoma skin cancer) and
women who emigrated or were lost to follow-up
immediately after recruitment, 10,633 participants were
followed, 3,966 of whom were recruited after menopause
(defined as absence of menstruation over the previous
12 mo). Cases and controls were obtained from these
postmenopausal women. Women were censored at date
of cancer diagnosis, death (n = 474), loss to follow-up
(n = 329), or end of follow-up, whichever came first.
Case Selection. Cases were women diagnosed with
breast cancer after recruitment to ORDET but before
December 31, 2003 (a median follow-up of 13.5 y). One
hundred eighty-four breast cancer cases were identified.
Of these, three were eliminated because breast cancer
was not their first cancer (they were censored at the date
of first cancer diagnosis) and another five were elimina-
ted because serum was not available. A further seven
caseswere eliminated because levels of follicle-stimulating
hormone (<5 Ag/mL) and luteinizing hormone (<3 Ag/L)
were in the premenopausal range. Thus, 169 cases were
analyzed, including 7 diagnosed with in situ breast
cancer. All cases were confirmed by pathology reports.
Control Selection. Up to four controls, matched to
cases by age (F3 y) and length of storage of serum
samples (F180 d), were chosen at random from all cohort
members alive and free of breast cancer at the time of
diagnosis of the matched case. An incidence density
sampling protocol for control selection was used, such
that controls could include women who later became
cases (14 women), and could also serve as controls more
than once (42 women). A total of 703 controls were
selected initially by the sampling protocol. However, 20
were eliminated because follicle-stimulating hormone,
luteinizing hormone, and progesterone levels were in the
premenopausal range, so 683 women served as controls.
Serum Analysis. Serum samples were stored at 80jC
for a mean of 17 y. There were no thawing accidents.
Case and control samples were removed from the freezer
together (within a few minutes) and sent to laboratory
together in a single container packed with dry ice. Case
samples were assayed together with their matched con-
trol samples (i.e., in the same batch) and all laboratory
personnel were blind to case versus control status. The
samples were analyzed by the Centro Medico Diagnos-
tico Emilia (Bologna, Italy).
Total estradiol was determined using the Orion
Diagnostica Spectra Estradiol Sensitive RIA kit (Orion
Diagnostica Oy). Total and free testosterone were
analyzed by solid-phase RIA (Coat-A-Count procedure
from Siemens Medical Solutions Diagnostics Ltd.). Sex
hormone–binding globulin (SHBG) was analyzed by
automated solid-phase chemiluminescent immunoassay
(Immulite 1000 Analyzer from Siemens Medical Solu-
tions Diagnostics).
Quality control was done at three concentrations for
SHBG and total and free testosterone and four concen-
trations for total estradiol. In each batch, quality control
samples were evaluated in quadruplicate. Within-batch
quality control coefficients of variation were 1.7% (high
concentration) and 21.3% (low concentration) for estra-
diol; 6.2% and 11.2%, respectively, for total testosterone;
6.9% and 12.8%, respectively, for free testosterone;
and 3.8% and 4.3%, respectively, for SHBG. Average
between-batch coefficients of variation were 6.6% (high)
and 21.4% for estradiol (low), 7.7% and 15.0% for total
testosterone, 15.7% and 22.4% for free testosterone, and
4.6% and 8.3% for SHBG.
ER, PR, and HER2 Status. Information on ER, PR, and
HER2 status was collected from pathology records.
When the information was not available (ER in 66 cases,
PR in 67, and HER2 in 69), immunohistochemical
determinations were carried out on paraffin-embedded
blocks of tumor tissue archived in pathology laborato-
ries in the Province of Varese. The determinations were
done at the Molecular Biology Unit Laboratories of the
National Cancer Institute, Milan. The following anti-
bodies were used: anti-HER2 CB11 (Ylem), anti-ER
(diluted 1:200, clone 1D5; DBA), and anti-PR MAb1A6
(diluted 1:100; DBA). An automated immunostainer
(Dako TechMate 1000) and peroxidase-streptavidin
revelation were used. Negative controls were incubated
with nonimmune serum from species in which the
primary antibody was produced. Sections of tumor with
known reactivity to each antibody were used as positive
controls. Sections were considered ER+ or PR+ when
>10% of cancer cells were labeled in the nucleus. Sections
were considered HER2+ when intense membrane immu-
nostaining was present in over 10% of cancer cells. In
Italy, the HER2 assay and result interpretation are
standardized (17).
Statistical Analysis. Descriptive statistics of breast
cancer risk factors and mean serum levels of hormones
and SHBG were used to compare cases and controls. The
significance of case-control differences in mean hormone
exposure levels was evaluated by paired comparisons
(t tests) of case values with the average of the four
matched controls in each case-control set. Relative risks
(RR) for developing breast cancer were calculated by
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conditional logistic regression (18). Serum levels of the
various hormones and SHBG were examined both as
continuous variables and by quartiles based on the fre-
quency distribution in controls. The potential confoun-
ders age at menarche, age at first birth (nulliparous, <25,
>25 y old), age at menopause, and history of breast
cancer in first-degree relatives (yes/no) were included in
the fully adjusted model. We excluded a further 4 cases
and 11 controls from the fully adjusted model because
values of confounder variables were missing (165 cases
and 672 controls analyzed). Tests of linear trend were
done using the median of each quartile.
Separate analyses were done to examine the associa-
tion between levels of sex hormones/SHBG and breast
cancer risk by receptor status. To do this, we categorized
cases by receptor status (ER+, ER, PR+, and PR) and
also identified three groups based on joint ER/PR status:
ER+/PR+, ER+/PR, and ER/PR. There were too few
ER/PR+ cases (n = 5), so this category was eliminated.
For these analyses, hormones/SHBG were categorized
into tertiles; age, age at menarche, age at first birth,
breast-feeding (yes/no), age at menopause, and history
of breast cancer in first-degree relatives (yes/no) were
included as confounders.
To test for differences in hormone/SHBG levels by
receptor status, we used polychotomous logistic regres-
sion (19) with three end points for ER status (ER+, ER,
and no breast cancer), PR status (PR+, PR, and no
breast cancer), and HER2 status (HER2+, HER2, and
no breast cancer) and four end points for combined
receptor status (ER+/PR+, ER+/PR, ER/PR, and no
breast cancer). Heterogeneity was investigated by the
Wald test on tertile trends. The analyses were done with
Stata version 7.
Results
Table 1 shows the characteristics of the 165 cases and 672
controls. Compared with controls, cases had a higher
frequency of family history of breast cancer, lower fre-
quency of breast-feeding, and lower past use of oral con-
traceptives. Cases were also slightly older at menopause,
Table 1. Baseline characteristics of postmenopausal case and control subjects
Controls (n = 672) Cases (n = 165)
n (%) n (%)
Education (y)
V5 445 (66.12) 102 (61.45)
6-8 127 (19.02) 45 (27.11)
>8 100 (14.86) 19 (11.45)
Hormone therapy use*
Yes 135 (20.30) 40 (24.54)
No 530 (79.70) 123 (75.46)
Oral contraceptive use*
Yes 84 (12.50) 13 (7.88)
No 588 (87.50) 152 (92.12)
Breast-feeding
Yes 511 (75.93) 120 (72.29)
No 162 (24.07) 46 (27.71)
Age at first birth
Nulliparous 65 (10.42) 15 (9.04)
Age <25 274 (43.91) 68 (40.96)
Age >25 285 (45.67) 83 (50.00)
Family breast cancer
Yes 50 (7.43) 22 (13.25)
No 622 (92.57) 144 (86.75)
n Mean F SD n Mean F SD
Age at baseline 671 58.10 F 5.33 165 58.02 F 5.31
Smoking (pack-years) 670 2.91 F 7.38 163 3.42 F 8.61
Age at menarche 672 13.29 F 1.56 165 13.24 F 1.55
Age at menopause 672 48.86 F 4.76 165 49.21 F 4.49
Full-term pregnancy 672 2.09 F 1.25 165 2.05 F 1.23
BMI* at baseline 670 26.31 F 4.14 165 26.46 F 4.36
*Past use.
Table 2. Geometric means (95% CI) of serum sex hormone concentrations in case and control subjects
Controls Cases P for difference
Mean Mean
Total testosterone (nmol/L) 0.86 (0.83-0.90) 0.97 (0.90-1.05) 0.006
Free testosterone (pmol/L) 1.86 (1.74-2.00) 1.93 (1.72-2.17) 0.629
Estradiol (pmol/L) 22.1 (20.4-24.0) 19.2 (17.0-21.8) 0.031
SHBG (nmol/L) 94.1 (88.9-99.6) 82.2 (75.7-89.3) 0.002
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younger at menarche, and smoked more (median pack-
years).
Levels of sex hormones and SHBG varied markedly
between cases and controls, being higher in cases for total
testosterone, free testosterone, and estradiol and lower
for SHBG (Table 2). Table 3 shows adjusted RRs of
developing breast cancer by quartiles of hormone/SHBG
levels. Women in the highest quartile of total testosterone
had a significantly greater risk [RR, 3.13; 95% confidence
interval (95% CI), 1.86-5.28] of developing breast cancer
than those in the lowest quartile (reference). After adjust-
ments for age at menarche, age at first birth, age at meno-
pause, and family history of breast cancer, the association
between total testosterone and breast cancer risk was
slightly stronger (RR, 3.28; 95% CI, 1.93-5.55 in the highest
quartile). The test for trend was significant (P < 0.001).
Women in the highest quartile of free testosterone had
a significantly greater risk (RR, 2.74; 95% CI, 1.60-4.69) of
developing breast cancer than those in the lowest quartile
(reference). After adjustments for the same confounders
used for total testosterone, the RR increased to 2.86 (95%
CI, 1.66-4.94) in the highest quartile. The trend was again
significant (P < 0.001).
No association of estradiol levels with breast cancer
risk was found, although RR estimates were in the same
direction as those for total and free testosterone.
Furthermore, RRs of breast cancer did not vary signifi-
cantly with SHBG. RR estimates remained unchanged
after adjustment for body mass index (BMI; data not
shown).
We examined whether the increased breast cancer
risks related to high levels of total and free testosterone
were independent of estradiol levels. We found that
estradiol-adjusted RRs of breast cancer were slightly
greater than non–estradiol-adjusted RRs (data not
shown). When the analyses were restricted to cases
diagnosed with breast cancer 6 months or more after
blood sampling, RRs were unchanged compared with
those given by the main analysis (data not shown).
Table 4 shows the results of the analysis of the risk of
developing breast cancer expressing specified receptors,
in relation to hormone/SHBG levels. The strongest
associations were with total testosterone in ER+ cases
(RR, 2.65; 95% CI, 1.62-4.32, highest versus lowest tertile),
PR+ cases (RR, 2.32; 95% CI, 1.33-4.06, highest versus
lowest tertile), and PR cases (RR, 2.47; 95% CI, 1.29-4.75,
highest versus lowest tertile). Tests for heterogeneity
between ER+ and ER, and between PR+ and PR, were
not significant.
When relations between hormone/SHBG level and
risk of breast cancer expressing various combinations of
receptor were assessed, risk of ER+/PR+ and ER+/PR
cancers were significantly associated with high total
testosterone (Table 5). The RR for ER+/PR+ cancer was
2.33 (95% CI, 1.31-4.15) in the highest total testosterone
tertile versus the lowest and the RR for ER+/PR cancer
was 3.06 (95% CI, 1.31-7.16). Tests for heterogeneity to
assess differences between ER/PR and ER+/PR+ and
ER+/PR subgroups, respectively, were not statistically
significant.
Table 3. Crude and adjusted RRs of developing breast cancer with 95% CI for quartiles of total testosterone, free
testosterone, estradiol, and SHBG in serum of postmenopausal women of the ORDET cohort
Cases/controls Crude RR (95% CI) Adjusted RR* (95% CI)
Total testosterone (median nmol/L)
1 (0.48) 25/181 1.00 1.00
2 (0.73) 31/153 1.50 (0.85-2.66) 1.48 (0.83-2.64)
3 (0.97) 45/148 2.36 (1.37-4.06) 2.39 (1.38-4.13)
4 (1.34) 64/160 3.13 (1.86-5.28) 3.28 (1.93-5.55)
P for trend
c
<0.001 <0.001
Continuous
b
1.54 (1.27-1.88) 1.58 (1.29-1.93)
Free testosterone (median pmol/L)
1 (0.66) 26/162 1.00 1.00
2 (1.32) 40/163 1.55 (0.90-2.69) 1.60 (0.92-2.78)
3 (2.15) 38/162 1.57 (0.89-2.77) 1.56 (0.88-2.78)
4 (3.68) 61/155 2.74 (1.60-4.69) 2.86 (1.66-4.94)
P for trend
c
<0.001 <0.001
Continuous
b
1.34 (1.11-1.62) 1.36 (1.13-1.65)
Estradiol (median pmol/L)
1 (8.1) 32/161 1.00 1.00
2 (16.5) 47/160 1.50 (0.90-2.49) 1.47 (0.88-2.44)
3 (23.5) 40/161 1.32 (0.77-2.24) 1.33 (0.78-2.28)
4 (36.5) 46/160 1.46 (0.87-2.46) 1.50 (0.88-2.54)
P for trend
c
0.267 0.216
Continuous
b
1.09 (0.90-1.33) 1.09 (0.90-1.33)
SHBG (median nmol/L)
1 (48.6) 47/161 1.00 1.00
2 (77.4) 35/160 0.71 (0.42-1.19) 0.69 (0.41-1.17)
3 (102.0) 50/161 1.00 (0.61-1.63) 0.98 (0.59-1.61)
4 (149.0) 33/160 0.66 (0.39-1.12) 0.66 (0.39-1.13)
P for trend
c
0.253 0.267
Continuous
b
0.86 (0.70-1.05) 0.86 (0.71-1.05)
*Adjusted for age at first birth, age at menarche, age at menopause, and family history of breast cancer.
cP value for trend from model with the median of quartiles entered as continuous variables.
bLog transformed.
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Finally, the association of hormone/SHBG level with
the risk of developing breast cancers expressing/not
expressing the HER2 receptor was evaluated (Table 6).
The increased risk of breast cancer associated with high
total testosterone was independent of the HER2 status of
the cancer (RR, 3.49; 95% CI, 1.09-11.2 for HER2+ cancer;
RR, 2.24; 95% CI, 1.39-3.60 for HER2; in both cases for
highest total testosterone tertile versus lowest). High free
testosterone was significantly associated with increased
risk of HER2 cancer (RR, 1.70; 95% CI, 1.06-2.73).
High estradiol levels tended to be associated with
increased risk of HER2 cancer and inversely associated
with HER2+ cancer. The test for heterogeneity between
HER2+ and HER2 cancers was statistically significant
(P = 0.027). When SHBG was considered as a continuous
variable, a decreased risk of HER2 breast cancer was
observed. We consider this an artifact due to the not
normal distribution because there is no trend and no
theoretical justification.
We further investigated the association of sex hor-
mone/SHBG with the risk of so-called triple-negative
cancers (ER/PR/HER2, only 14 cases) but found no
significant association between levels of hormones/SHBG
and the risk of this poor-prognosis breast cancer subtype.
Discussion
In 1996, we published a case-control study using the first
24 postmenopausal breast cancer cases diagnosed in the
ORDET cohort; we found that high levels of testosterone
and of estradiol in serum were associated with increased
breast cancer risk (6). Ten years on, with 165 cases
diagnosed, the results of this present study support the
original finding that high prediagnostic serum testos-
terone is significantly associated with increased risk of
breast cancer. The strongest effect was that of high total
testosterone on the risk of developing ER+/PR+ and ER+/
PR cancers. Other studies have implicated testosterone
in breast cancer risk, including a pooled analysis of nine
prospective cohort studies (7).
The present analysis failed to confirm the significant
association of high serum estradiol with increased breast
cancer risk, found in our previous study. However,
confidence intervals were wide and compatible with
those of previous cohort studies, which reported RRs
of f2 for prediagnostic estrogen levels in the upper
quartile or quintile (7, 9). The lack of significant asso-
ciation in the present study might also be explained by
the fact that estradiol was measured using a different
analytic technique to that in our previous study (20). The
new technique has a higher coefficient of variation, but it
is more practicable for analyses of large numbers of
samples and might have limited our ability to detect an
association. We also found that high estradiol was asso-
ciated (non significantly) with increased risk of HER2,
but not HER2+ cancers, with significant heterogeneity
between these two cancer types; however, we only had
23 HER2+ cancers.
Table 4. Adjusted RRs of developing ER+, ER, PR+, and PR breast cancer in relation to hormone levels in
postmenopausal women of the ORDET cohort
Total testosterone
(median nmol/L)
ER+ ER PR+ PR
Cases/
controls
RR*
(95% CI)
Cases/
controls
RR*
(95% CI)
Cases/
controls
RR*
(95% CI)
Cases/
controls
RR*
(95% CI)
1 (0.56) 28/231 1.00 10/231 1.00 22/231 1.00 15/231 1.00
2 (0.87) 38/200 1.58 (0.93-2.67) 7/200 0.83 (0.31-2.22) 32/200 1.72 (0.97-3.08) 14/200 1.06 (0.50-2.25)
3 (1.25) 61/193 2.65 (1.62-4.32) 13/193 1.62 (0.69-3.80) 42/193 2.32 (1.33-4.06) 30/193 2.47 (1.29-4.75)
P for trend
c
<0.001 0.237 0.003 0.004
Continuous
b
1.61 (1.30-2.00) 1.18 (0.80-1.74) 1.52 (1.20-1.92) 1.50 (1.13-2.00)
P heterogeneityx 0.39 0.64
Free testosterone (median pmol/L)
1 (0.80) 34/208 1.00 7/208 1.00 25/208 1.00 16/208 1.00
2 (1.67) 36/208 1.05 (0.63-1.75) 10/208 1.45 (0.54-3.89) 28/208 1.14 (0.64-2.03) 18/208 1.10 (0.55-2.23)
3 (3.28) 57/208 1.64 (1.03-2.62) 13/208 1.89 (0.74-4.83) 43/208 1.71 (1.00-2.91) 25/208 1.56 (0.81-3.01)
P for trend
c
0.023 0.192 0.036 0.156
Continuous
b
1.30 (1.06-1.59) 1.24 (0.85-1.82) 1.35 (1.08-1.70) 1.20 (0.91-1.59)
P heterogeneityx 0.92 0.82
Estradiol (median pmol/L)
1 (10.1) 38/208 1.00 11/208 1.00 25/208 1.00 24/208 1.00
2 (19.3) 41/208 1.09 (0.67-1.77) 9/208 0.83 (0.33-2.04) 35/208 1.41 (0.81-2.46) 13/208 0.56 (0.28-1.13)
3 (32.5) 48/208 1.26 (0.79-2.02) 10/208 0.92 (0.38-2.23) 36/208 1.46 (0.84-2.54) 22/208 0.92 (0.50-1.69)
P for trend
c
0.321 0.887 0.214 0.893
Continuous
b
1.12 (0.91-1.38) 0.92 (0.66-1.28) 1.24 (0.96-1.60) 0.91 (0.73-1.15)
P heterogeneityx 0.54 0.35
SHBG (median nmol/L)
1 (54.9) 41/208 1.00 11/208 1.00 29/208 1.00 22/208 1.00
2 (91.6) 47/209 1.10 (0.69-1.76) 10/209 0.86 (0.36-2.09) 39/209 1.28 (0.75-2.16) 19/209 0.84 (0.44-1.60)
3 (141.0) 39/207 0.97 (0.60-1.57) 9/207 0.81 (0.33-2.00) 28/207 0.98 (0.56-1.72) 18/207 0.83 (0.43-1.60)
P for trend
c
0.871 0.655 0.881 0.595
Continuous
b
0.89 (0.74-1.07) 0.91 (0.63-1.30) 0.86 (0.69-1.06) 0.91 (0.70-1.19)
P heterogeneityx 0.74 0.74
*Adjusted for age, age at first birth, and family history of breast cancer.
cP value for trend from model with the median of tertiles entered as continuous variables.
bLog transformed.
xWald test for heterogeneity.
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We found no association of BMI with breast cancer
risk or with estradiol, total testosterone, or free testos-
terone levels. These findings are in direct contrast to
those of a collaborative analysis of eight prospective
studies (21), which indicated increased breast cancer risk
with increasing BMI in postmenopausal women, which
was largely explained by an increase in estrogens with
BMI.
Whereas the mechanism by which estrogens promote
breast cancer seems fairly well established (22), the
mechanism of action of androgens is more obscure and it
is unclear whether they affect breast cancer by directly
stimulating the proliferation of breast cells or whether
they serve simply as estrogen precursors. Another
possible link between high androgens and breast cancer
could be via metabolic syndrome, a condition charac-
terized by high insulin levels that stimulate ovarian
synthesis of androgen (23). In women, metabolic syn-
drome is associated with increased testosterone levels
(24, 25). Other characteristics of metabolic syndrome may
independently increase breast cancer risk (26).
We tried to address the issue of whether testosterone
exerts its effect via circulating estrogens by doing a
multivariate analysis in which serum testosterone levels
were adjusted for estradiol levels. We found that the
association of testosterone with breast cancer not only
persisted but also became slightly stronger after adjus-
ting for estradiol level, clearly suggesting that the
androgen acts by mechanisms other than simply increas-
ing estrogens. It is important to note, however, that in
previous studies, adjustment for estrogen levels resulted
in attenuation of the RR associated with serum testos-
terone (3, 7, 9).
We found that high levels of testosterone were
primarily associated with increased risk of ER+/PR+
and ER+/PR cancers, as also found by the Nurses
Health Study (8) and a cohort study that examined only
ER+ tumors (10). This association of testosterone with
ER+ cancers is biologically plausible because testosterone
maybe converted by aromatase within tumor cells into
estrogens to directly stimulate tumor cell proliferation
(27). Much less is known about the influence of
testosterone on PR; however, PRs are induced by ER,
and the presence of PR is a marker of a functional ER
(28). Although few studies have assessed the receptor
expression of subsequent tumors in relation to hormone
levels (8, 10, 11, 29), more have investigated tumor
receptor status in relation to hormone-related factors
such as nulliparity, early menarche, and delayed
childbearing. From these studies too, it seems that the
risk is confined to receptor-positive tumors (ER+PR+)
with no appreciable elevation in risk of receptor-negative
cancers (ERPR; refs. 30-33). These factors have been
proposed to confer risk by increasing systemic exposure
to cycling reproductive hormones (30, 34).
To our knowledge, this is the first prospective study to
investigate whether sex hormone/SHBG levels are
associated with the risk of HER2+ or HER2 breast
Table 5. Adjusted RRs of developing ER+PR+, ER+PR, and ERPR breast cancers in relation to hormone levels in
postmenopausal women of the ORDET cohort
Total testosterone (median nmol/L) ER+PR+ ER+PR ERPR
Cases/controls RR* (95% CI) Cases/controls RR* (95% CI) Cases/controls RR* (95% CI)
1 (0.56) 20/231 1.00 8/231 1.00 7/231 1.00
2 (0.87) 30/200 1.76 (0.97-3.21) 8/200 1.11 (0.41-3.04) 6/200 1.01 (0.33-3.08)
3 (1.25) 39/193 2.33 (1.31-4.15) 20/193 3.06 (1.31-7.16) 10/193 1.80 (0.67-4.84)
P for trend
c
0.005 0.005 0.227
Continuous
b
1.53 (1.20-1.95) 1.76 (1.23-2.50) 1.16 (0.75-1.80)
P heterogeneityx 0.77 0.35 —
Free testosterone (median pmol/L)
1 (0.80) 22/208 1.00 12/208 1.00 4/208 1.00
2 (1.67) 27/208 1.24 (0.68-2.26) 9/208 0.71 (0.29-1.73) 9/208 2.30 (0.70-7.61)
3 (3.28) 40/208 1.79 (1.02-3.14) 15/208 1.20 (0.54-2.64) 10/208 2.59 (0.80-8.43)
P for trend
c
0.033 0.495 0.153
Continuous
b
1.36 (1.08-1.73) 1.13 (0.80-1.59) 1.33 (0.86-2.05)
P heterogeneityx 0.79 0.49 —
Estradiol (median pmol/L)
1 (10.1) 22/208 1.00 16/208 1.00 8/208 1.00
2 (19.3) 33/208 1.51 (0.85-2.69) 7/208 0.45 (0.18-1.12) 6/208 0.76 (0.26-2.24)
3 (32.5) 34/208 1.54 (0.87-2.74) 13/208 0.82 (0.38-1.76) 9/208 1.10 (0.41-2.91)
P for trend
c
0.179 0.690 0.793
Continuous
b
1.26 (0.97-1.64) 0.92 (0.69-1.23) 0.90 (0.63-1.28)
P heterogeneityx 0.68 0.64 —
SHBG (median nmol/L)
1 (54.9) 28/208 1.00 12/208 1.00 10/208 1.00
2 (91.6) 34/209 1.17 (0.68-2.01) 13/209 1.08 (0.48-2.43) 6/209 0.56 (0.20-1.59)
3 (141.0) 27/207 0.98 (0.56-1.72) 11/207 0.97 (0.41-2.25) 7/207 0.67 (0.25-1.81)
P for trend
c
0.892 0.467 0.451
Continuous
b
0.80 (0.55-1.18) 1.00 (0.71-1.40) 0.80 (0.55-1.18)
P heterogeneityx 0.53 0.59 —
*Adjusted for age, age at first birth, and family history of breast cancer.
cP value for trend from model with the median of tertiles entered as continuous variable.
bLog transformed.
xWald test for heterogeneity.
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cancers in postmenopausal women. We found that high
total testosterone was associated with increased risk of
cancers both expressing and not expressing this epider-
mal growth factor receptor, whereas high free testoster-
one was only associated with increased risk of HER2
disease. The increased risk agrees with the finding of the
only previous case-control study that investigated sex
hormone levels and the HER2 status of the cancers (29).
We found that high estradiol levels tended to be
associated with increased risk of HER2 cancer and
inversely associated with the risk of HER2+ cancer. It is
interesting that in our study, a positive association
between estradiol levels and breast cancer risk in the
whole cohort was not observed but that HER2 receptor
status conferred significant heterogeneity on the relation
between breast cancer risk and estradiol levels. The
absence of an association between estradiol levels and
risk of HER2+ cancer is consistent with the fact that
HER2+ cancers typically do not express ER or PR and do
not respond to tamoxifen (35, 36). Evidence is growing
that factors influencing hormonal status (e.g., parity, age
at menarche, age at menopause, and pregnancy), and
also the presence of BRCA1 or BRCA2 gene mutations,
only influence the risk of developing HER2 breast
cancers (14, 37).
The fact that testosterone was associated with both
HER2+ and HER2 cancers again suggests that testoster-
one acts to increase cancer risk by mechanisms other than
via its conversion to estrogen. HER2 overexpression
occurs in 15% to 30% of invasive breast cancers and is
associated with worsened prognosis (38). HER2+ cancers
are usually also high grade, contain high numbers of
proliferating cells (KI67+), show chromosomal aneu-
ploidy, and, as noted previously, do not express ER or
PR (39).
When we investigated whether sex hormone/SHBG
levels were associated with changed risk of developing
so-called triple-negative cancers (ER, PR, and HER2),
which are known to have a poor prognosis (40), we did
not find significant associations, but the number of cases
was very small.
The strengths of this study are its prospective design,
the fact that reproductive history and other participant
data were obtained before diagnosis (reducing problems
of recall bias), and the fact that blood was also sampled
before diagnosis. The main source of hormone receptor
data was medical records, but when this information was
missing, immunohistochemical determinations were
done on archived tumor specimens. Although hormone
receptor status was determined in most cases by
immunohistologic methods, different laboratories may
have used different cutoffs separating receptor-positive
from receptor-negative tumors, which may have blurred
differences between ER+ and ER tumors.
To conclude, this study provides further evidence that
high levels of circulating testosterone increase the risk of
developing breast cancer in postmenopausal women.
The cancers that develop are mainly ER+ (ER+PR+ or
Table 6. Adjusted RRs of HER2+ and HER2 breast cancer in relation to hormone levels in postmenopausal women
of the ORDET cohort
HER2+ HER2
Cases/controls RR* (95% CI) Cases/controls RR* (95% CI)
Total testosterone (median nmol/L)
1 (0.56) 4/231 1.00 32/231 1.00
2 (0.87) 7/200 2.02 (0.58-7.04) 36/200 1.32 (0.79-2.21)
3 (1.25) 12/193 3.49 (1.09-11.2) 58/193 2.24 (1.39-3.60)
P for trend
c
0.030 0.001
Continuous
b
1.93 (1.26-2.95) 1.45 (1.18-1.79)
P heterogeneityx 0.53
Free testosterone (median pmol/L)
1 (0.80) 7/208 1.00 33/208 1.00
2 (1.67) 7/208 0.98 (0.34-2.85) 37/208 1.13 (0.68-1.88)
3 (3.28) 9/208 1.14 (0.40-3.20) 56/208 1.70 (1.06-2.73)
P for trend
c
0.785 0.018
Continuous
b
1.35 (0.87-2.12) 1.27 (1.04-1.55)
P heterogeneityx 0.46
Estradiol (median pmol/L)
1 (10.1) 12/208 1.00 34/208 1.00
2 (19.3) 5/208 0.43 (0.15-1.26) 41/208 1.21 (0.74-1.99)
3 (32.5) 6/208 0.43 (0.15-1.24) 51/208 1.54 (0.95-2.48)
P for trend
c
0.095 0.087
Continuous
b
0.86 (0.61-1.21) 1.15 (0.93-1.43)
P heterogeneityx 0.027
SHBG (median nmol/L)
1 (54.9) 7/208 1.00 42/208 1.00
2 (91.6) 8/209 0.95 (0.32-2.77) 48/209 1.11 (0.70-1.76)
3 (141.0) 8/207 1.18 (0.42-3.32) 36/207 0.86 (0.53-1.40)
P for trend
c
0.736 0.514
Continuous
b
1.30 (0.82-2.07) 0.82 (0.69-0.99)
P heterogeneityx 0.52
*Adjusted for age, age at first birth, and family history of breast cancer.
cP value for trend from model with the median of tertiles entered as continuous variable.
bLog transformed.
xWald test for heterogeneity.
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiol Biomarkers Prev 2009;18(1). January 2009
175
on July 30, 2019. © 2009 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
ER+PR); the risk of developing ERPR cancers might
not be increased. Although HER2+ and HER2 breast
cancers were both associated with high total testosterone,
they showed opposing associations with serum estrogen.
This is not surprising because breast cancer is not a single
disease but a group of diseases distinguished by different
behavioral and molecular characteristics whose patho-
geneses are also likely to differ. Further studies, however,
are required to elucidate how high levels of circulating
sex hormones can promote particular subtypes of breast
cancer.
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